Blumhouse Pivots to Franchise

Blumhouse Productions, founded by Jason Blum in 2000, has been for most of its operating history the specific institutional embodiment of the low-budget-high-margin horror-production economy. The company’s best-known productions (the Paranormal Activity series, The Purge series, Get Out, Happy Death Day, The Invisible Man) were produced at budgets between $3 million and $15 million and collectively generated billions in theatrical revenue.

Blumhouse’s 2024 and 2025 production slates indicate that this model is being substantially adjusted. The company is pivoting toward larger-budget franchise production, horror-adjacent genre expansion, and more conventional studio-style development. The pivot is commercially rational. It is also, for the broader horror ecosystem, a specific loss.

The old model, specified

The Blumhouse model, as it operated from roughly 2007 through 2022, involved specific production discipline:

Fixed budget caps. Most Blumhouse productions were capped at $5 million or under. Higher-budget productions (The Invisible Man at $7 million, M3gan at $12 million) were exceptional rather than routine.

Talent back-end compensation. Directors, writers, and lead performers took smaller-than-industry-standard up-front fees in exchange for back-end participation in any commercial upside. This structure shifted financial risk from production to the post-release revenue, and allowed Blumhouse to fund productions with limited capital.

Creative autonomy. Directors operated with unusual creative autonomy for their budget tier, with Blum himself notoriously hands-off during production. The autonomy was a specific recruitment advantage; Blumhouse attracted director talent that larger studios at similar budget tiers did not.

First-dollar gross after breakeven. Blumhouse’s profit-share arrangements were specifically structured to give participants meaningful upside if the film commercially broke out. Get Out (2017) at a $4.5 million budget generated hundreds of millions in back-end for its creative team.

This model produced an extraordinary run of commercially successful director-driven horror films. It also produced significant industry-level value, providing the career-development pipeline for horror directors (Jordan Peele, Leigh Whannell, Mike Flanagan, Jennifer Kent, and others) who have subsequently moved to larger productions.

The pivot

Across 2023 and 2024, Blumhouse’s production slate has shifted in specific ways:

Budget levels have increased. Five Nights at Freddy’s (2023) was produced at approximately $20 million, well above the historic Blumhouse ceiling. Speak No Evil (2024) came in at approximately $15 million. The upcoming The Black Phone 2 (announced for 2025) has been reported at a similar level.

Franchise properties have dominated. The recent slate is heavily weighted toward sequels and established-IP properties (Freddy’s, Speak No Evil, Exorcism, M3gan 2.0) rather than original productions. The original-to-franchise ratio has inverted from the historic 70/30 to approximately 30/70.

Partnership structures have shifted. Blumhouse has been partnering more frequently with other studios for co-production and distribution arrangements. The 2024 partnership with Atomic Monster (James Wan’s production company) is the most visible of these arrangements.

The creative-autonomy profile has tightened. Multiple directors who have worked with Blumhouse recently have, in industry reporting, indicated that the studio’s creative oversight has increased relative to the historic low-intervention approach.

Why the pivot is rational

Blumhouse’s historic model depended on specific market conditions that have deteriorated.

Theatrical-window economics. The Blumhouse model required a robust theatrical run (six to twelve weeks) to generate the back-end revenue that its profit-share arrangements depended on. The compressed post-pandemic theatrical window has reduced the commercial opportunity for a $4 million horror film to the point that the economics no longer work as cleanly as they did in the 2010s.

Production-cost inflation. The specific $5 million production budget of 2015 does not purchase the same production in 2024. Union-negotiated pay scales, post-strike increases, and general cost inflation have pushed the minimum viable budget for a theatrically-released horror film with professional production values up substantially.

Audience discovery changes. Blumhouse’s historic productions found their audiences through a combination of viral-trailer campaigns, specific festival premieres (particularly the Overlook Film Festival and TIFF Midnight Madness), and genre-press amplification. The audience-discovery pathways have shifted, with TikTok-native content now dominating the specific horror-audience attention allocation. The viral-trailer marketing model no longer produces reliably predictable results.

Streamer competition. Streaming services have, since 2019, become aggressive bidders for horror content. Netflix and Amazon are willing to pay Blumhouse-like prices for horror productions and release them without theatrical windows, reducing the specific commercial opportunity theatrical horror depended on.

What is being lost

The broader industrial consequence of the Blumhouse pivot is that the specific career-development pathway for director-driven horror has been constrained.

The Blumhouse of 2013-2020 was the institutional vehicle through which specific directors got their second and third films made. Jordan Peele made Get Out and Us through Blumhouse. Leigh Whannell made Upgrade and The Invisible Man. Jennifer Kent made The Babadook (not with Blumhouse but in the adjacent indie-horror ecosystem that Blumhouse anchored). These directors, once established, moved to larger studios and larger productions.

The current ecosystem does not replace this pathway. A24 operates in the adjacent space but at a smaller scale and with less consistent horror output. Neon is smaller still. The major studios have mostly exited the mid-budget horror lane. If Blumhouse has also effectively exited it, the specific career path that produced the last decade’s American horror auteurs no longer functions.

This is what the pivot costs, at the industrial level. Blumhouse itself will continue producing horror films, profitably, at franchise scale. The next generation of horror directors, who would have gotten their careers started under the old model, will have to find a different pathway.

Where Blumhouse goes from here

The franchise pivot appears strategically stable. Freddy’s generated a successful $300 million global gross on its $20 million budget. M3gan generated approximately $180 million worldwide in 2023 (and the sequel is expected to perform similarly). The specific commercial logic for franchise-focused production is confirmed.

What is less clear is whether Blumhouse will retain a secondary pipeline of low-budget original productions. Blum has, in public statements, continued to emphasise the studio’s commitment to original work. The actual production volume tells a different story. The next three years will confirm whether the franchise-dominant pattern is temporary or permanent.

I am not expecting the original-production pipeline to return. The economics that supported it are structurally gone. Blumhouse, at scale, has made the commercially rational choice. The horror ecosystem will have to find a different way to develop its next generation.